RxDoctor Payments DataLook up a doctor →

Michael McHale, MD

Gynecologic Oncology · la Jolla, CANPI 1508828179

Payments from drug & device makers

$979,460in general payments, 2019–2025

Across 225 payments — averaging $4353.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$337K
  • GSK$137K
  • Iovance Biotherapeutics, Inc.$95K
  • AstraZeneca$93K
  • Alkermes, Inc.$90K
  • Tesaro, Inc.$80K
  • plus $147K from 16 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$979,460 in reported general payments places this provider in the 90th percentile of 152 gynecologic oncology providers in California.

See all gynecologic oncology providers in California

Medicare billing

Part B allowed, 2024
$67,638
Medicare patients
107
Services billed
378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →